At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 52 enrolled
Drug / intervention
Jaktinib Hydrochloride Tabletsdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Single-dose, Randomized, Open-label, Repeated Cross-over Pharmacokinetic Comparison Study of Two Formulations of Jaktinib Hydrochloride Tablets in Healthy Adult Volunteers Under Fasted Conditions
In Brief
A Phase 1 clinical trial evaluating Jaktinib Hydrochloride Tablets for Myelofibrosis. Completed, enrolled 52 participants across 1 site.
Detailed Summary
To evaluate the pharmacokinetic Characteristics of two formulations of Jaktinib Hydrochloride Tablets in Healthy Adult Volunteers
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMyelofibrosis
CountriesChina
Collaborators--
Timeline
Phase 1CompletedFinished
202420252026
First PostedNov 2023
Enrollment StartNov 2023
Primary CompletionDec 2023
TodayJul 2026
First PostedNov 15, 2023
Enrollment StartNov 29, 2023
Primary CompletionDec 20, 2023
TodayJul 1, 2026
Enrollment to primary: 21 daysPosted 2.6 years ago
Interventions
Jaktinib Hydrochloride Tabletsdrug
Orally, one tablet at a time